MaxCyte, Inc. Stock-Based Compensation
MaxCyte, Inc. (MXCT) reported Stock-Based Compensation of $2.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- MaxCyte, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.16M, a 66.99% decline year-over-year.
- MaxCyte, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.14M, a 62.45% decline year-over-year.
- MaxCyte, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $706.00K, a 77.47% decline year-over-year.
- MaxCyte, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.95M, a 42.02% decline year-over-year.
- MaxCyte, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $9.21M, a 29.58% decline from fiscal 2024.
- MaxCyte, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $13.08M, a 6.41% decline from fiscal 2023.
- MaxCyte, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $13.98M, a 18.95% increase from fiscal 2022.
- MaxCyte, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $11.75M, a 47.66% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.30M 10-Q · filed 2026-08-13 | $3.01M derived: sum of 3 quarters · filed 2026-08-13 | $4.96M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.14M 10-Q · filed 2026-05-13 | $1.85M derived: sum of 2 quarters · filed 2026-05-13 | $3.80M derived: sum of 3 quarters · filed 2026-05-13 | $7.32M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $706.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.66M derived: sum of 2 quarters · filed 2026-03-25 | $6.17M derived: sum of 3 quarters · filed 2026-08-13 | $9.21M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.47M derived: sum of 2 quarters · filed 2026-08-13 | $8.51M 10-Q · filed 2025-11-13 | $11.64M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.55M 10-Q · filed 2026-08-13 | $9.69M derived: sum of 3 quarters · filed 2026-08-13 | $13.06M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $3.04M 10-Q · filed 2026-05-13 | $6.17M derived: sum of 2 quarters · filed 2026-05-13 | $9.54M derived: sum of 3 quarters · filed 2026-05-13 | $13.11M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $6.50M derived: sum of 2 quarters · filed 2026-03-25 | $10.07M derived: sum of 3 quarters · filed 2026-03-25 | $13.08M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.93M derived: sum of 2 quarters · filed 2025-11-13 | $9.95M 10-Q · filed 2025-11-13 | $13.52M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $6.58M 10-Q · filed 2025-08-06 | $10.15M derived: sum of 3 quarters · filed 2025-08-06 | $13.76M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $3.02M 10-Q · filed 2025-05-08 | $6.59M derived: sum of 2 quarters · filed 2025-05-08 | $10.20M derived: sum of 3 quarters · filed 2025-05-08 | $13.72M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $7.18M derived: sum of 2 quarters · filed 2025-03-11 | $10.70M derived: sum of 3 quarters · filed 2025-03-11 | $13.98M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $7.13M derived: sum of 2 quarters · filed 2024-11-06 | $10.40M 10-Q · filed 2024-11-06 | $10.40M 10-Q · filed 2023-11-08 | $13.52M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $3.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $6.80M 10-Q · filed 2024-08-06 | $6.80M 10-Q · filed 2023-08-09 | $9.91M derived: sum of 3 quarters · filed 2024-08-06 | $13.11M derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-03-31 | $3.28M 10-Q · filed 2024-05-07 | $3.28M 10-Q · filed 2023-05-10 | $6.40M derived: sum of 2 quarters · filed 2024-05-07 | $9.59M derived: sum of 3 quarters · filed 2024-05-07 | $12.57M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $6.32M derived: sum of 2 quarters · filed 2024-03-12 | $9.29M derived: sum of 3 quarters · filed 2024-03-12 | $11.75M 10-K · filed 2024-03-12 | $11.75M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $3.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $6.17M derived: sum of 2 quarters · filed 2023-11-08 | $8.63M 10-Q · filed 2023-11-08 | $11.08M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $5.44M 10-Q · filed 2023-08-09 | $7.88M derived: sum of 3 quarters · filed 2023-08-09 | $10.17M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $2.46M 10-Q · filed 2023-05-10 | $4.91M derived: sum of 2 quarters · filed 2023-05-10 | $7.20M derived: sum of 3 quarters · filed 2023-05-10 | $9.10M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $4.73M derived: sum of 2 quarters · filed 2023-03-15 | $6.64M derived: sum of 3 quarters · filed 2023-03-15 | $7.96M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.19M derived: sum of 2 quarters · filed 2022-11-09 | $5.51M 10-Q · filed 2022-11-09 | $6.28M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $3.23M 10-Q · filed 2022-08-10 | $3.99M derived: sum of 3 quarters · filed 2022-08-10 | $4.59M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $1.32M 10-Q · filed 2022-05-09 | $2.09M derived: sum of 2 quarters · filed 2022-05-09 | $2.69M derived: sum of 3 quarters · filed 2022-05-09 | |||||
| 2020-12-31 | $767.20K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $1.37M derived: sum of 2 quarters · filed 2022-03-22 | $2.47M 10-K · filed 2022-03-22 | |||||
| 2020-09-30 | $598.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.70M 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $1.11M 10-Q · filed 2021-09-13 | |||||||
| 2019-12-31 | $1.75M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |